Breaks Categories: News

WednesdayMar 15, 2023 1:51 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results from IND-Enabling Toxicology Study of SP-26

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has achieved positive results for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. In collaboration with Experimur, a Frontage Laboratories company, Silo Pharma tested SP-26 in a toxicology and tolerability study in mini pigs using an ascending (descending) dosing regimen in advance of initiating clinical studies. “Today’s positive results are an important step as we move closer to achieving all needed components to plan human trials of SP-26.” said Eric Weisblum, chief executive officer of…

Continue Reading

TuesdayMar 14, 2023 1:25 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Acquires LIVEMOR Assets

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has acquired substantially all assets from LIVMOR, a digital health solutions company. Specifically, LIVMOR offers a patient-engaging remote monitoring system of critical physiological biomarkers. The acquisition allows HeartBeam to extend its reach with LIVEMOR’s FDA-cleared Halo+(TM) Atrial Fibrillation Detection System and its physician-prescribed integrated patient-care platform. The acquisition gives HeartBeam full ownership of the world’s first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring. HeartBeam and LIVMOR partnered earlier this year to build a HeartBeam-branded version…

Continue Reading

TuesdayMar 14, 2023 12:46 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Engages ShareIntel to Investigate Possible Naked Short Selling of Its Stock

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced that it has renewed the service agreement with ShareIntel-Shareholder Intelligence Services LLC (www.ShareIntel.com). Under the agreement, ShareIntel will assist in ongoing investigations related to suspected naked short selling of FSD Pharma’s common stock. “Our shareholders can rest assured that we have heard their concerns. We are acting appropriately with all tools at our disposal to identify any nefarious perpetrators. We, as fervent advocates for naked short…

Continue Reading

MondayMar 13, 2023 11:52 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Peer-Reviewed Study Results Published

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, has announced that results of its study have been published in the “International Journal of Molecular Sciences.” The study was designed to evaluate the anti-inflammatory effects of rare cannabinoids and their potential application for the treatment of skin conditions, including atopic dermatitis, psoriasis, pruritus and acne. The study is titled “Rare Phytocannabinoids Exert Anti-Inflammatory Effects on Human Keratinocytes via the Endocannabinoid System and MAPK Signalling Pathway.” According to the announcement, study results demonstrate the therapeutic potential of rare cannabinoids in the…

Continue Reading

MondayMar 13, 2023 11:36 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces It Has No Exposure to Silicon Valley Bank Issues

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank (“SVB”) due to liquidity concerns. CNS Pharmaceuticals does not hold any deposits or investments at SVB. To view the full press release, visit https://ibn.fm/SPCyI About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the…

Continue Reading

ThursdayMar 09, 2023 12:30 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Switzerland has been enrolled in the company’s ongoing global trial. The potentially pivotal trial is focused on evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. “The active patient enrollment we continue to build across our clinical trial sites in Europe is incredibly encouraging. Our team is laser focused on getting additional clinical trial sites online so that…

Continue Reading

WednesdayMar 08, 2023 12:47 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Makes Changes in Senior Leadership Roles

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has made key leadership changes. The company announced that HeartBeam president Robert Eno has been appointed executive vice president while current chief business officer Jon Hunt, PhD, will transition into the role of strategic advisor and consultant, effective March 15, 2023. According to the announcement, these changes are being made ahead of key 2023 milestones, including FDA clearance for the HeartBeam AIMI(TM) system and FDA submission of the HeartBeam AIMIGo(TM) 3D vector ECG first-generation product. The…

Continue Reading

WednesdayMar 08, 2023 12:35 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Veteran of Media Industry as Chief Content, Engagement Officer

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has announced a new chief content and engagement officer. Maureen Connolly, an award-winning content strategic and audience builder, will step into the position. According to the announcement, Connolly has 20-plus years of experience in the health, wellness, science and technology sectors. She has proven expertise in working with product, marketing, and engineering teams to create content platforms that enable and encourage engagement between businesses and global audiences while also building supportive, connected communities. “Maureen’s background, experience and passion couldn’t be better…

Continue Reading

WednesdayMar 08, 2023 12:16 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate at Oppenheimer 33rd Annual Health Care Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced that its Chief Executive Officer Doug Drysdale will participate at the Oppenheimer 33rd Annual Health Care Conference taking place on March 13-15, 2023. Drysdale’s fireside chat will be webcast live on Tuesday, March 14, at 12:40 p.m. ET. Interested parties should visit https://ibn.fm/4Qlqa to register for and access the webcast. The archived version will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/sxkbQ About Cybin Inc. Cybin is a leading ethical biopharmaceutical company working with…

Continue Reading

WednesdayMar 08, 2023 12:04 pm

BioMedNewsBreaks – Unicycive Therapeutics Inc. (NASDAQ: UNCY) Announces up to $130M to Commercialize and Launch Investigational New Drug

Unicycive (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, has announced its entry into a securities purchase agreement with certain health care-focused institutional investors that will provide up to $130 million in gross proceeds to Unicycive through a private placement. According to the announcement, the private placement includes initial upfront funding of $30 million. Vivo Capital is leading the funding with participation from RA Capital, BVF Partners, Logos Capital, and support by existing investors Nantahala Capital Partners and Rosalind Advisors Inc. In conjunction with the financing, Gaurav Aggarwal, M.D., managing director of Vivo Capital, will…

Continue Reading